Loading…
← CockpitCompetitor Analysis › 688658.SS Youcare Pharmaceutical Group Co. Ltd. Class AOpen in the cockpit ↗

Youcare Pharmaceutical Group Co. Ltd. Class A688658.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major
Momentum laggard 12
Mkt cap
$674M
US dollars, full cap
Free float
55%
of shares outstanding
$/day
$17.1M
20-day average traded
Fwd P/E
24.9×
forward earnings
ROIC−WACC
-11.3 pp
WACC 6.9%
Hurdle
n/a
no reverse DCF
Next earnings
156 days
23 Apr 2027
Close · CNYCN¥10.17
1D-2.4%
1W-13.1%
1M-19.4%
3M-25.0%
6M-48.8%
YTD-55.0%
1Y-50.5%
ATR %5.5%
52w lowhigh68.3% off high

What Youcare Pharmaceutical does

Employees: 2,870

Youcare Pharmaceutical at a glance

Size Youcare Pharmaceutical (688658.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $674M, the 2979th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥10.17 on 18 Nov 2026.

Performance Over six months the shares fell 48.8%, against -6.0% for the median peer and -20.0% for the China market (cap-weighted) — lowest of 21 in its peer set.

Growth Revenue fell 7.3% over the last twelve months (peer median +11.6%); the operating margin is -13.2% (peer median 10.7%).

Valuation It trades at 24.9× forward earnings against a peer median of 17.0× (4th most expensive of 9).

Capital Return on invested capital runs 11.3 points below its cost of capital (6.9% WACC).

Next results Next results expected around 23 Apr 2027 (exchange calendar; dates can move).

Relative performance

608010021 May 202621 Aug 202618 Nov 2026Peer median 94688658.SS 53
Six months, rebased to 100: Youcare Pharmaceutical against the median of its 20 peers (local-currency closes).

Youcare Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥2.36BCN¥2.42BCN¥3.75BCN¥4.16BCN¥4.50B
Revenue growth—-35%-10%-8%—
Gross profitCN¥1.37BCN¥1.11BCN¥2.06BCN¥2.52BCN¥2.83B
EBITDAn/a-CN¥25.3MCN¥385MCN¥379MCN¥406M
Net income-CN¥318M-CN¥262MCN¥124MCN¥185MCN¥335M
Free cash flow-CN¥8.08MCN¥209MCN¥79.9MCN¥288M-CN¥668M
Capital expenditureCN¥104MCN¥135MCN¥359MCN¥497MCN¥548M
Total debtCN¥861MCN¥738MCN¥915MCN¥678MCN¥558M

Quarterly statements and history in the cockpit →

Youcare Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-25%0%+25%+50%-20%-10%0%PHIL688488ANNX6003510009154985SPARCFDCNVCTINNOVACAP000566300016412345340570300878603998ABUSSGMT688658.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Youcare Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

0%+100%+200%+300%50×100×PHIL6884880009154985INNOVACAP3000164534603998688658.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Youcare Pharmaceutical is the large dot.

Youcare Pharmaceutical competitors and peer comparison

How Youcare Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Youcare Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure688658.SSPeer medianRank in peer set
1-month return-19.4%-2.8%3rd lowest of 21
6-month return-48.8%-6.0%lowest of 21
Distance from 52-week high-68.3%-28.2%lowest of 21
Revenue growth (TTM)-7.3%+11.6%4th lowest of 18
Operating margin-13.2%10.7%3rd lowest of 18
Forward P/E24.9×17.0×4th most expensive of 9
ROIC minus cost of capital-11.3 pp-0.0 pp2nd lowest of 15

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Youcare Pharmaceutical 688658.SSChina$674M-49%-7%-13%24.9×n/an/a
Philogen PHIL.MIItaly$672M-11%+295%79%10.1×n/an/a
Jiangsu Aidea Pharmaceutical 688488.SSChina$672M-35%+7%8%112.1×31.9%+19.8%
Annexon ANNXUnited States$671M-30%n/an/an/an/an/a
Yabao Pharmaceutical 600351.SSChina$678M0%-3%16%n/a-8.3%-2.8%
Shandong Wit Dyne Health 000915.SZChina$687M-31%-36%36%9.1×n/an/a
Earth 4985.TJapan$687M+7%+4%4%18.0×-1.6%-1.8%
Sun Pharma Advanced Research SPARC.NSIndia$660M+6%+3,141%84%n/an/an/a
FDC FDC.NSIndia$653M+3%+10%14%n/a25.2%+10.3%
Nuvectis Pharma NVCTUnited States$698M+91%n/an/an/an/an/a
HPGC Renmintongtai Pharmaceutical 600829.SSChina$701M-6%+4%2%n/a4.0%+5.3%
Innova Captab INNOVACAP.NSIndia$645M+20%+37%12%32.2×27.1%+31.4%
Hainan Haiyao 000566.SZChina$642M-18%-18%-50%n/an/an/a
Beijing Beilu Pharmaceutical 300016.SZChina$641M-19%+23%11%79.7×9.1%+7.9%
Center Laboratories 4123.TWOTaiwan$639M-29%+14%9%n/a36.3%+16.2%
Mochida Pharmaceutical 4534.TJapan$714M-3%+16%10%16.1×n/an/a
China Traditional Chinese Medicine 0570.HKHong Kong$716M-31%-16%0%n/an/an/a
Zhejiang Wecome Pharmaceutical 300878.SZChina$632M-18%+92%-41%n/an/an/a
Hunan Fangsheng Pharmaceutical 603998.SSChina$719M-1%+12%20%13.7×-4.8%+6.4%
Arbutus Biopharma ABUSUnited States$630M-6%+1,143%80%n/an/an/a
Sagimet Biosciences SGMTUnited States$722M+52%n/an/an/an/an/a

Questions

Which companies are Youcare Pharmaceutical's closest peers?
The cockpit's peer set: Philogen (PHIL.MI), Jiangsu Aidea Pharmaceutical (688488.SS), Annexon (ANNX), Yabao Pharmaceutical (600351.SS), Shandong Wit Dyne Health (000915.SZ), Earth (4985.T), Sun Pharma Advanced Research (SPARC.NS), FDC (FDC.NS).
Is Youcare Pharmaceutical expensive compared with its peers?
On forward p/e it trades at 24.9× against a peer median of 17.0×, 4th most expensive of 9 in its peer set.
How has Youcare Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -48.8% against -6.0% for the median peer; over one year -50.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.